In the HARMONY Alliance Study of European randomized clinical trials, researchers sought to determine if MRD could serve as an intermediate endpoint in intensively treated AML.

The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.

MRD negativity post-chemotherapy strongly predicts improved overall survival in AML, with a significant reduction in mortality risk. The study suggests MRD could serve as an earlier surrogate endpoint ...

Measurable residual disease after induction therapy may serve as an individual-level predictor of survival among patients ...

Molecular minimal residual disease status may offer clues as to which patients with acute monocytic leukemia will benefit from certain therapies. After patients with acute monocytic leukemia (AML) ...

ORLANDO, Dec. 6, 2025) Sensitive tests designed to detect very small numbers of remaining leukemia cells after treatment, known as measurable ...

NPM1 minimal residual disease (MRD) positivity before allogeneic hematopoietic cell transplantation is linked to higher relapse rates and lower overall survival in patients with acute myeloid leukemia ...

SAN DIEGO — Allogeneic stem cell transplant is associated with a significant survival benefit in patients with NPM1-mutated acute myeloid leukemia (AML) who are in their first complete remission and ...

This transcript has been edited for clarity. Gail J. Roboz, MD: Hi, everyone. My name is Dr Gail Roboz. I'm a professor of medicine and director of the leukemia program at Weill Cornell Medicine and ...

Azacitidine-venetoclax showed superior event-free survival and overall response rates compared to traditional induction ...